Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial

• Published in: Respiratory medicine and research 2020-11, Vol.78, p.100770-100770, Article 100770
• Main Authors: Bejan-Angoulvant, T., Naccache, J.-Marc, Caille, A., Borie, R., Nunes, H., Ferreira, M., Cadranel, J., Crestani, B., Cottin, V., Marchand-Adam, S.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Resistance - drug effects; Drug Therapy, Combination; Female; France; Humans; Idiopathic Interstitial Pneumonias - drug therapy; Immunosuppressive Agents - therapeutic use; Interstitial lung desease; Life Sciences; Male; Middle Aged; Mycophenolate mofetil; Mycophenolic Acid - administration & dosage; Mycophenolic Acid - adverse effects; Nonspecific interstitial pneumonia; Pulmonary fibrosis; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Treatment Outcome
• ISSN: 2590-0412; 2590-0412
• DOI: 10.1016/j.resmer.2020.100770

Nonspecific interstitial pneumonia (NSIP) are rare but severe diseases, with high mortality and morbidity, with no effective pharmacological treatment allowing for long-term remission, and therefore no clear therapeutic recommendations. Classic immunosuppressants are used as first-line treatment, with only one third of patients being responders and no clear recommendations exist for the choice of the second-line therapy. The EvER-ILD study is the first one to prospectively evaluate the efficacy and safety of rituximab and mycophenolate mofetil (MMF) versus placebo and MMF in a broad range of NSIP patients that did not respond to a first-line therapy. A pharmacokinetic-pharmacodynamic analysis based on rituximab serum concentrations will allow identification of potential factors associated with therapeutic response and/or adverse effects. EvER-ILD study is a French multicenter, prospective, randomized, double blind, placebo-controlled, superiority trial. Patients with severe and progressive NSIP non-responding to a first line immunosuppressive treatment will be randomized in 2 groups of treatment: one course of rituximab plus 6 months MMF (RTX-MMF group) and one course of placebo plus 6 months MMF (Placebo-MMF group). The primary outcome is the change in Forced Vital Capacity (FVC, % of predicted) from baseline to 6 months. Several clinical, biological, and quality of life secondary outcomes will be measured at 3, 6 and 12 months. A sample size of 122 patients (61 patients per group) would allow to show a point difference between groups in the change of FVC at 6 months, based on a common standard deviation for FVC change of 8% with a power of 90%, alpha 5% two-sided, and anticipating an extreme 10% drop-out rate. The protocol was approved by the French Research Ethics Committee (CPP Tours Ouest 1 2016-R28) on November 10, 2016, and by the French competent authority (ANSM, reference 160771A-22) on December 1st, 2016. This article refers to protocol V2, dated November 18, 2016. An independent data safety monitoring board will review safety and tolerability data for the duration of the trial. Results will be disseminated via peer reviewed publication and presentation at international conferences. NCT02990286 (clinicaltrials.gov), EudraCT 2016-003026-16 (European Medicines agency).